These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 19182203)

  • 1. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory.
    Jing W; Gershan JA; Johnson BD
    Blood; 2009 Apr; 113(18):4449-57. PubMed ID: 19182203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of CD25⁺ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma.
    Jing W; Yan X; Hallett WH; Gershan JA; Johnson BD
    Blood; 2011 Jun; 117(25):6952-62. PubMed ID: 21521781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine.
    Jing W; Orentas RJ; Johnson BD
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):277-92. PubMed ID: 17317581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YB-1 immunization combined with regulatory T-cell depletion induces specific T-cell responses that protect against neuroblastoma in the early stage.
    Zheng J; Liu P; Yang X
    Acta Biochim Biophys Sin (Shanghai); 2012 Dec; 44(12):1006-14. PubMed ID: 23169344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.
    Croce M; Corrias MV; Orengo AM; Brizzolara A; Carlini B; Borghi M; Rigo V; Pistoia V; Ferrini S
    Int J Cancer; 2010 Sep; 127(5):1141-50. PubMed ID: 20039320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.
    Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ
    J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
    Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D
    Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model.
    Chakrabarti L; Morgan C; Sandler AD
    PLoS One; 2015; 10(6):e0129237. PubMed ID: 26079374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
    Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
    Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.
    Chung Y; Qin H; Kang CY; Kim S; Kwak LW; Dong C
    Blood; 2007 Sep; 110(6):2013-9. PubMed ID: 17581919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity.
    Rigo V; Corrias MV; Orengo AM; Brizzolara A; Emionite L; Fenoglio D; Filaci G; Croce M; Ferrini S
    Cancer Immunol Immunother; 2014 May; 63(5):501-11. PubMed ID: 24647609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine.
    Webster WS; Thompson RH; Harris KJ; Frigola X; Kuntz S; Inman BA; Dong H
    J Immunol; 2007 Sep; 179(5):2860-9. PubMed ID: 17709500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognate CD4 help is essential for the reactivation and expansion of CD8 memory T cells directed against the hematopoietic cell-specific dominant minor histocompatibility antigen, H60.
    Ryu SJ; Jung KM; Yoo HS; Kim TW; Kim S; Chang J; Choi EY
    Blood; 2009 Apr; 113(18):4273-80. PubMed ID: 19139082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
    Viehl CT; Moore TT; Liyanage UK; Frey DM; Ehlers JP; Eberlein TJ; Goedegebuure PS; Linehan DC
    Ann Surg Oncol; 2006 Sep; 13(9):1252-8. PubMed ID: 16952047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    Hu HM; Winter H; Urba WJ; Fox BA
    J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy.
    Xu L; Xu W; Jiang Z; Zhang F; Chu Y; Xiong S
    Cancer Biol Ther; 2009 Jan; 8(1):66-72. PubMed ID: 19029829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.
    Wang LX; Li Y; Yang G; Pang PY; Haley D; Walker EB; Urba WJ; Hu HM
    Eur J Immunol; 2010 May; 40(5):1375-85. PubMed ID: 20186876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
    Frangione V; Mortara L; Castellani P; De Lerma Barbaro A; Accolla RS
    Int J Cancer; 2010 Oct; 127(7):1614-24. PubMed ID: 20091859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.